Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSA fine for J&J

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson will pay $511,000 in fines because imports of pseudoephedrine-containingBenedryl-D to a manufacturing facility in Lititz, Pa., were not reported as required by the Controlled Substances Act, according to an Aug. 5 settlement with the Department of Justice. The U.S. Attorney's Office for the Eastern District of Pennsylvania and J&J subsidiary McNeil-PPC explain the unreported imports of the OTC nasal decongestant tablets occurred during 2001 to 2005, when Pfizer's Warner-Lambert business owned the facility. J&J acquired the facility in 2006 when it bought Pfizer Consumer Healthcare (1"The Tan Sheet" Dec. 18, 2006, p. 9). DOJ says the CSA requires companies to file reports with the Drug Enforcement Agency within 15 days of importing products containing pseudophedrine and other specified chemicals that can be used in manufacturing controlled substances...

You may also be interested in...

J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business

Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says

The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.

China May Ease Data Transfer Rules But Regulatory Ambiguity Remains

China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts